Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.
Department of Hematology, Roskilde University Hospital, Koegevej 7, 4000 Roskilde, Denmark. Electronic address: christenla@gmail.com.
Christen Lykkegaard
CL
Andersen
Department of Hematology, Roskilde University Hospital, Koegevej 7, 4000 Roskilde, Denmark.
Mads Emil
ME
Bjørn
Department of Haematology, Queen' University Belfast, 97 Lisburn Road, Belfast BT9 7AB, Northern Ireland, United Kingdom.
Mary Frances
MF
McMullin
Department of Haematology, Guy's and St Thomas; NHS Foundation Trust, Great Maze Pond, London SE1 9R, United Kingdom.
Claire
C
Harrison
Department of Internal Medicine, Stockholm South Hospital, 118 83 Stockholm, Sweden.
Jan
J
Samuelsson
Department of Hematology, Uppsala University Hospital, SE-751 85, Uppsala, Sweden.
Elisabeth
E
Ejerblad
Department of Hematology, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Sonja
S
Zweegman
Department of Haematology, Russells Hall Hospital, Dudley DY1 2HQ, United Kingdom.
Savio
S
Fernandes
Department of Haematology, Russells Hall Hospital, Dudley DY1 2HQ, United Kingdom.
David
D
Bareford
Department of Haematology, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom.
Steven
S
Knapper
Hematology Center, Karolinska University Hospital, SE-141 86 Stockholm, Sweden.
Eva
E
Löfvenberg
Division of Hematology, Department of Medicine, Örebro University Hospital, SE-701 85 Örebro, Sweden.
Olle
O
Linder
Department of Hematology, Uddevalla Hospital, NU Hospital Organization, SE-451 80, Sweden.
Bjørn
B
Andreasson
Division of Hematology, Department of Medicine, Örebro University Hospital, SE-701 85 Örebro, Sweden.
Erik
E
Ahlstrand
Department of Hematology, Herlev Hospital, Herlev Ringvej, 2730 Herlev, Denmark.
Morten Krogh
MK
Jensen
Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen O, Denmark.
Ole Weis
OW
Bjerrum
Department of Hematology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Hanne
H
Vestergaard
Department of Internal Medicine, (Hematological Department), Viborg Hospital, Heibergs alle 4, 8800 Viborg, Denmark.
Herdis
H
Larsen
Department of Hematology, Herlev Hospital, Herlev Ringvej, 2730 Herlev, Denmark.
Tobias Wirenfeldt
TW
Klausen
Department of Hematology, Esbjerg Hospital, Finsensgade 35, 6700 Esbjerg, Denmark.
Torben
T
Mourits-Andersen
Department of Clinical Genetics, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Vibe
V
Skov
Department of Clinical Genetics, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Mads
M
Thomassen
Department of Clinical Genetics, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Torben
T
Kruse
Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen O, Denmark.
Kirsten
K
Grønbæk
Department of Hematology, Roskilde University Hospital, Koegevej 7, 4000 Roskilde, Denmark.
Hans Carl
HC
Hasselbalch
D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000032:analysis; D000071451:Chitinase-3-Like Protein 1; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000097:blood / Q000188:drug therapy*; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy*; D000077337:Vorinostat
D054392:Adipokines; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D037102:Lectins; D000077337:Vorinostat; D002097:C-Reactive Protein
Essential thrombocythemia; Phase II study; Polycythemia vera; Vorinostat; Ykl-40